216 related articles for article (PubMed ID: 24640976)
1. NMDA antagonists as Parkinson's disease therapy: disseminating the evidence.
Majláth Z; Vécsei L
Neurodegener Dis Manag; 2014; 4(1):23-30. PubMed ID: 24640976
[TBL] [Abstract][Full Text] [Related]
2. Amantadine in Parkinson's disease: pro and contra.
Greulich W; Fenger E
J Neural Transm Suppl; 1995; 46():415-21. PubMed ID: 8821077
[TBL] [Abstract][Full Text] [Related]
3. Renaissance of amantadine in the treatment of Parkinson's disease.
Blanchet PJ; Metman LV; Chase TN
Adv Neurol; 2003; 91():251-7. PubMed ID: 12442683
[No Abstract] [Full Text] [Related]
4. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease.
Verhagen Metman L; Del Dotto P; van den Munckhof P; Fang J; Mouradian MM; Chase TN
Neurology; 1998 May; 50(5):1323-6. PubMed ID: 9595981
[TBL] [Abstract][Full Text] [Related]
5. Current pharmacotherapeutic treatment options in Parkinson's disease.
Rezak M
Dis Mon; 2007 Apr; 53(4):214-22. PubMed ID: 17586328
[TBL] [Abstract][Full Text] [Related]
6. Prospects of glutamate antagonists in the therapy of Parkinson's disease.
Blandini F; Greenamyre JT
Fundam Clin Pharmacol; 1998; 12(1):4-12. PubMed ID: 9523179
[TBL] [Abstract][Full Text] [Related]
7. Modulation of levodopa-induced motor response complications by NMDA antagonists in Parkinson's disease.
Blanchet PJ; Papa SM; Metman LV; Mouradian MM; Chase TN
Neurosci Biobehav Rev; 1997 Jul; 21(4):447-53. PubMed ID: 9195602
[TBL] [Abstract][Full Text] [Related]
8. Blockade of glutamatergic transmission as treatment for dyskinesias and motor fluctuations in Parkinson's disease.
Verhagen Metman L; Del Dotto P; Blanchet PJ; van den Munckhof P; Chase TN
Amino Acids; 1998; 14(1-3):75-82. PubMed ID: 9871445
[TBL] [Abstract][Full Text] [Related]
9. Glutamate/dopamine D1/D2 balance in the basal ganglia and its relevance to Parkinson's disease.
Starr MS
Synapse; 1995 Apr; 19(4):264-93. PubMed ID: 7792721
[TBL] [Abstract][Full Text] [Related]
10. The role of glutamate in the pathophysiology of Parkinson's disease.
Blandini F; Greenamyre JT; Nappi G
Funct Neurol; 1996; 11(1):3-15. PubMed ID: 8936453
[No Abstract] [Full Text] [Related]
11. [New therapeutic possibilities with low-affinity NMDA receptor antagonists].
Kornhuber J; Weller M
Nervenarzt; 1996 Jan; 67(1):77-82. PubMed ID: 8676993
[TBL] [Abstract][Full Text] [Related]
12. Excitotoxicity and new antiglutamatergic strategies in Parkinson's disease and Alzheimer's disease.
Koutsilieri E; Riederer P
Parkinsonism Relat Disord; 2007; 13 Suppl 3():S329-31. PubMed ID: 18267259
[TBL] [Abstract][Full Text] [Related]
13. New pharmacological avenues for the treatment of L-DOPA-induced dyskinesias in Parkinson's disease: targeting glutamate and adenosine receptors.
Blandini F; Armentero MT
Expert Opin Investig Drugs; 2012 Feb; 21(2):153-68. PubMed ID: 22233485
[TBL] [Abstract][Full Text] [Related]
14. Glutamate release inhibition ineffective in levodopa-induced motor complications.
Bara-Jimenez W; Dimitrova TD; Sherzai A; Aksu M; Chase TN
Mov Disord; 2006 Sep; 21(9):1380-3. PubMed ID: 16758479
[TBL] [Abstract][Full Text] [Related]
15. Altered tryptophan metabolism in Parkinson's disease: a possible novel therapeutic approach.
Szabó N; Kincses ZT; Toldi J; Vécsei L
J Neurol Sci; 2011 Nov; 310(1-2):256-60. PubMed ID: 21824629
[TBL] [Abstract][Full Text] [Related]
16. Effect of a selective glutamate antagonist on L-dopa-induced dyskinesias in drug-naive parkinsonian monkeys.
Hadj Tahar A; Grégoire L; Darré A; Bélanger N; Meltzer L; Bédard PJ
Neurobiol Dis; 2004 Mar; 15(2):171-6. PubMed ID: 15006686
[TBL] [Abstract][Full Text] [Related]
17. Differing effects of N-methyl-D-aspartate receptor subtype selective antagonists on dyskinesias in levodopa-treated 1-methyl-4-phenyl-tetrahydropyridine monkeys.
Blanchet PJ; Konitsiotis S; Whittemore ER; Zhou ZL; Woodward RM; Chase TN
J Pharmacol Exp Ther; 1999 Sep; 290(3):1034-40. PubMed ID: 10454475
[TBL] [Abstract][Full Text] [Related]
18. Drug treatments of levodopa-induced dyskinesias.
Vale S
Lancet; 1999 Aug; 354(9177):511. PubMed ID: 10465195
[No Abstract] [Full Text] [Related]
19. [Medicinal treatment of idiopathic Parkinson's disease].
Klockgether T
Nervenarzt; 2003 Mar; 74 Suppl 1():S12-21. PubMed ID: 12624679
[TBL] [Abstract][Full Text] [Related]
20. Dextromethorphan improves levodopa-induced dyskinesias in Parkinson's disease.
Verhagen Metman L; Del Dotto P; Natté R; van den Munckhof P; Chase TN
Neurology; 1998 Jul; 51(1):203-6. PubMed ID: 9674803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
